Mucoactive phytopreparations with ivy extract in pediatrics: efficacy, safety and economic feasibility
Keywords:
mucoactive phytopreparations, ivy extract, efficiency, safety, economic feasibilityAbstract
Acute bronchitis is an infectious inflammatory disease of the lower respiratory tract which occurs at any age. The main symptom of acute bronchitis is non-productive (dry) or productive (wet) cough. The main goal in treating acute bronchitis with productive cough is to increase expectoration, including with the help of mucoactive drugs. In clinical practice, herbal medicines are increasingly used to eliminate symptoms of the disease and to suppress inflammation. The advantage of herbal coughs medicines is that various compounds of herbal ingredients are able to enhance the desired effects and neutralize side effects. Among the numerous expectorant herbal preparations, only a few, namely, preparations of common ivy, thyme and primrose, have the most complex effect: they increase mucus secretion and motility, reduce respiratory tract tone and inhibit inflammation. A comparative pharmacoeconomic analysis of medicines based on ivy extract in the form of syrup which are available on the pharmaceutical market showed that treatment with Gederin Ivy Syrup is the optimal from a pharmacoeconomic point of view. The combination of such effects of ivy extract in the preparation Gederin Ivy, as expectorant (mucokinetic and secretolytic), bronchospasmolytic and anti-inflammatory, predetermines its pronounced clinical efficacy for the treatment of cough, as well as good tolerance, allow it to be widely used in the complex therapy of bronchitis in pediatric practice.
References
Anti-inflammatory effects of ivy leaves dry extract: influence on transcriptional activity of NFκB. (2018). Inflammopharmacology. 27 (2). https://doi.org/10.1007/s10787-018-0494-9; PMid:29748881 PMCid:PMC6482290
Chernikov VV. (2012). Primenenie preparatov rastitelnogo proishozhdeniya dlya lecheniya kashlya u detey. PF. 6: 105-109.
Ernst E. (2007). Herbal medicines: balancing benefits and risks. Novartis Found Symp. 282: 154-167. Discussion 167-172, 212-218. https://doi.org/10.1002/9780470319444.ch11; PMid:17913230
Fazio S, Pouso J, Dolinsky D, Fernandez A, Hernandez M, Clavier G et al. (2009). Tolerance, safety and efficacy of Hedera helix extract in inflammatory bronchial diseases under clinical practice conditions: a prospective, open, multicentre postmarketing study in 9657 patients. Phytomedicine. 16 (1): 17-24. https://doi.org/10.1016/j.phymed.2006.05.003; PMid:16860549
Greunke C, Hage-Hulsmann A, Sorkalla T, Keksel N, Haberlein F, Haberlein H. (2015). A systematic study on the influence of the main ingredients of an ivy leaves dry extract on the b2-adrenergic responsiveness of human airway smooth muscle cells. Pulm Pharmacol Ther. 31: 92-98. https://doi.org/10.1016/j.pupt.2014.09.002; PMid:25234924
Hersh AL, Shapiro DJ, Pavia AT et al. (2011). Antibiotic Prescribing in Ambulatory Pediatrics in the United States. Pediatrics. 128: 1053-1061. https://doi.org/10.1542/peds.2011-1337; PMid:22065263
Hocaoglu AB, Karaman O, Erge DO et al. (2012). Effect of Hedera helix on lung histopathology in chronic asthma. Iran J Allergy Asthma Immunol. 11: 316-323.
Holzinger F, Jean-Franc, Chenot O. (2011). Systematic Review of Clinical Trials assessing the effectiveness of Ivy Leaf (Hedera Helix) for acute upper respiratory tract infections. Evidence-Based Complementary and Alternative Medicine: 9. Article ID 382789. https://doi.org/10.1155/2011/382789; PMid:20976077 PMCid:PMC2957147
Korovina NA. (2000). Kashel u detey: posobie dlya vrachey. Moskva: Posad: 48.
Kronenberg RS, Griffith DE. (1994). Bronchitis and acute febrile tracheobronchitis. In: Respiratory infections. A scientific basis for management. Ed. Niederman, Sarosis, Glassroth. New York: W B Saunders Company: 91-102.
Kryuchko TA, Tkachenko OYa, Vovk YuA. (2014). Lechenie kashlya u detey: ot raznoobraziya podhodov k logicheskomu vyivodu. Pediatriya. Vostochnaya Evropa. 3: 131-140.
Marquardt P, Kaft K, Nieber K. (2015). Clinical trials with herbal medicinal products in children: a literature analysis. Wien Med Wochenschr. 165 (11-12): 236-242. https://doi.org/10.1007/s10354-015-0373-6; PMid:26183729
Namazova-Baranova LS, Kotlyarova MS, Rovenskaya YuV i dr. (2014). Sravnenie effektivnosti i bezopasnosti fito- i antibiotikoterapii pri lechenii ostrogo bronhita u detey: rezultatyi mnogotsentrovogo dvoynogo slepogo randomizirovannogo klinicheskogo issledovaniya. Pediatricheskaya farmakologiya. 11 (5): 22-29. doi. org/10.15690/pf.v11i5.1161.
Nyquist AC, Gonzales R, Steiner JF, Sande MA. (1998). Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA. 279 (11): 875-877. https://doi.org/10.1001/jama.279.11.875; PMid:9516004
Schmidt M, Thomsen M, Schmidt U. (2012). Suitability of ivy extract for the treatment of paediatric cough. Phytother Res. 26 (12): 1942-19. https://doi.org/10.1002/ptr.4671; PMid:22532491
Schulte-Michels Janka, Wolf Anne, Aatz Stefan et al. (2016). α-Hederin inhibits G-protein-coupled receptor kinase2-mediated phosphorylation of β2-adrenergic receptors. Phytomedicine. 23: 52-57. https://doi.org/10.1016/j.phymed.2015.12.001; PMid:26902407
Shann F, Thomas D, Hart K. (2003). Acute lower respiratory tract infections in children: possible criteria for selection of patients for antibiotic therapy and hospital admission. Bull World Health Organ. 81 (4): 301-305.
Sieben A, Prenner L, Sorkalla T, Wolf A, Jakobs D, Runkel F, Haberlein H. (2009). α-Hederin, but not hederacoside C and hederagenin from Hedera helix, affects the binding behaviour, dynamics and regulation of beta 2-adrenergic receptors. Biochemistry. 48: 3477-3482. https://doi.org/10.1021/bi802036b; PMid:19278262
Smith SM, Fahey T, Smucny J, Becker LA. (2004). Antibiotics for acute bronchitis. Cochrane Database of Systematic Reviews: 4. Art. No.: DC000245. CD000245.pub2. https://doi.org/10.1002/14651858
Soroka ND, Korshunova EV, Ryabyih OV, Balatskaya GM, Kuznetsova NV, Belan EYu. (2010). Effektivnost i bezopasnost ingalyatsionnogo metoda lecheniya suhim ekstraktom listev plyuscha ostryih respiratornyih zabolevaniy u detey rannego vozrasta. Lechaschiy vrach. 6: 14.
Suleyman H, Mshvildadze V, Gepdiremen A, Elias R. (2003). Acute and chronic antiinflammatory profile of the ivy plant, Hedera helix, in rats. Phytomedicine. 10: 370-374. https://doi.org/10.1078/0944-7113-00260; PMid:12834000
Tumanov VA, Pokanevich VV, Garnik TP, Frolov VM, Peresadin NA. (2012). Phytotherapy: application modern lines in medical practice and perspectives of the further development. Phytoterapiya. (1): 4–11.
World Health Organization. (2010). WHO monographs on medicinal plants commonly used in the Newly Independent States (NIS). Geneva: WHO-Press: 464.
Downloads
Published
Issue
Section
License
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
